The United States Pharmacopeia (USP) updated the vitamin K2 MK-7 analysis monograph to include a step for testing microencapsulated MK-7 powder. Vitamin K2 is not stable in high-alkaline formulations such as with calcium or magnesium. Newly released USP 42-NF37 2S reflects the market development of K2 stability solutions while reducing the risk of false-negative results and the need for re-testing.
Kappa's 2019 Formulation LookBook is a compendium of 150 ready-to-launch white-label product concepts that are backed by consumer market reseach, stability trials and established supply chains.
Free of charge Label Claim Testing
Shelf stability is vital to successful K2 products –ensuring quality to customers and brands.
Do your K2 MK-7 products meet label claim?
Are they pure, all-trans bioactive MK-7?
The Kappa portfolio of premium ingredients represents a team of Superheroes for the bone and heart dietary supplements health categories.
Kappa deeply believes in the promise of vitamin K2 MK-7 and has a mission to improve health and well-being globally. Kappa developed the K2 Academy as a learning center on all facets of vitamin K2, from history to health, manufacturing to final formulation. The Academy includes a range of tools in a variety of formats educate new distributors, customers and the public on the promise of K2VITAL®.
The origin of K2VITAL® dates back to 2006, when Norwegian researcher, Dr Inger Reidun Aukrust, together with her team, discovered a process to produce all-trans Vitamin K2, MK-7, using natural compounds such as geraniol and farnesol in a strictly controlled synthesis process. The significance of the process for all-trans vitamin K2 MK-7 has been recognised and patented. For vitamin K’s, two stereo chemical versions can exist: cis and trans forms of the molecule. The cis form remains biologically inactive, while the trans form has a full biological potential.